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Various types of stressful conditions can have unique and important effects on immunity 
and can lead to dramatic consequences to health. For my University Scholar project, the 
characteristic biomarker signatures produced from a set of diverse stressors (e.g. psychological, 
biological and chemical) are being investigated. A biomarker signature is a distinctive biological 
indicator of a specific condition. High-throughput tools for the measurement of different cellular 
products have the potential to further our understanding of human disease and facilitated the 
identification of new biomarkers in all areas of medicine. The hypothesis that each form of 
stress, psychological, chemical and physical, will elicit different biomarker signatures is being 
tested. In order to examine the biomarker signatures associated with various stressors, samples 
from individuals who have experiences one of several forms of stress will be evaluated.  The 
biological samples to be tested include human saliva samples taken from patients who had 
experienced psychological trauma.  We hypothesize that distinctive changes to the biomarker 
signature found in these patients’ saliva may facilitate the identification of those with post 
traumatic stress disorder (PTSD) and ultimately may enable a more effective treatment regimen.  
To quantify the differential expression profiles of the salivary components of the biomarker 
signature (including interleukins, chemokines, TNF, interferon, heat shock proteins, melatonin, 
and procalcitonin) traditional enzyme-linked immunosorbent assay (ELISA) as well as Surface 
Plasmon Enhanced Fluorescence (SPEF) techniques will be utilized.  By categorizing the unique 
endogenous responses that are associated with each stressful condition, better diagnosis could be 
made and the effects of different stresses may be better predicted and controlled. Categorizing 
and quantifying different biomarker signatures of individuals experiencing different stressors 









Biomarkers are features that can be objectively measured and evaluated as an indicator of 
a normal biological process, a pathogenic process, or a pharmacological response to a therapeutic 
intervention (Biomarkers Definitions Working Group. 2001). A biomarker can be used as an 
indicator of a biological state; it is a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to 
a therapeutic intervention. Limits to using biomarkers as a diagnostic tool exist. Using only a 
single indicator leaves room for false positives in the population of healthy individuals with high 
levels of that specific substance, or false negatives, diseased individuals with lower levels of the 
indicator. This inaccuracy can be reduced by use of biomarker signatures. A biomarker signature 
is an integration of simultaneous biomarker measurements that generate a predictive pattern or 
signature of a biological state. Analysis of large analyte sets can generate biomarker signatures 
of disease or stress exposure that has diagnostic potential.   
In addition to diagnostic uses, biomarker signatures have potential implications with 
therapeutics. Certain therapeutic interventions can only be effective in subpopulations 
(Trusheim, Berndt, Douglas 2007). Biomarker signatures have the potential to be useful for 
identifying patients that are more likely to benefit or to experience an adverse reaction in 
response to a given therapy; thereby more effectively treat diseases. For example, clinicians now 
commonly test to determine which breast tumors over-express the human epidermal growth 




factor receptor type 2 (HER2), which is associated with a worse prognosis but also predicts a 
better response to the medication trastuzumab (Hamburg and Collins 2010).  . The development 
of tools for high-throughput analysis has increased the determination of biomarkers that can be 
used for personalized medicine. Characterization of various biomarkers could aid in the 
avoidance of harmful adverse effects and maximize treatment success. Additionally, assessment 
of an individual’s susceptibility to certain diseases before they become apparent should also be 
possible. The use of biomarker signatures for predicting onset and prognoses of diseases allows 
time to set out a plan for prevention, treatment and monitoring that is specific for an individual 
patient.  
 
The Links between Stress and the Immune Response 
The immune system is a highly regulated system which is divided into innate and 
adaptive responses. The nervous system plays a role in the regulation of immunity through 
neuroendocrine responses which control inflammation at a systemic level via two axes; the 
hypothalamic-pituitary-adrenal axis (HPA axis) and the sympathetic-adrenal medullary (SAM) 
axis (Sternberg 2006).  The central cells of the immune system (lymphocytes, monocytes, etc.) 
display receptors for some neuroendocrine products of the HPA and SAM axes (Padgett and 
Glaser 2003). Chronic stress is associated with the activation of the hypothalamic–pituitary–
adrenal (HPA) axis, as well as with the depression of immune function. Acute stress is associated 
with activation of the sympatho–adreno–medullary system, which is reflected by salivary a-
amylase and chromogranin A (Soo-Quee Koh and Choon-Huat Koh 2007).  
Psychological stressors increase glucocorticoid levels through increased adrenal activity 
which leads to an inhibition of the functions of lymphocytes, macrophages and monocytes. 




Chronic activation of the HPA axis and the SAM axis, results in chronic production of 
glucocorticoid hormones and catecholamines (Padgett and Glaser 2003). Glucocorticoid 
receptors expressed on a variety of immune cells bind cortisol which indirectly regulates the 
activity of immune cells capable of producing cytokines. Adrenergic receptors bind 
catecholamines (epinephrine and norepinephrine) and activate the transcription of genes 
encoding for a variety of cytokines. The changes in gene expression mediated by glucocorticoid 
hormones and catecholamines can lead to immune system dysregulation. The relationship 
between stress, the HPA endocrine system and immunity is complex. The multi-directional 
relationship between the different systems of the body provide the foundation to my hypothesis 
that different forms of stress will affect the nervous, endocrine, and immune systems in unique 
ways that are reflected in the unique biomarker signatures associated with each stress.  
 
Biomarker Signatures of Various Stress Forms: Literature Review 
An enormous amount of work has been done linking conditions such as post-traumatic 
stress disorder (Gill et al. 2009), psychologically stressful situations (Depke et al. 2009) and 
various chemical exposures (Pruett et al. 2009) to various immune-altering effects. As high 
throughput technology becomes more popular and the technology more accurate, biomarker 
signatures of many conditions have been studied as potential diagnostic tools, prognosis 
predictors,  as well as means to determine the most effective treatment options.  
 
Biomarker Signature of Traumatic Brain Injury   
Traumatic brain injury (TBI) is a complex injury with a broad spectrum of symptoms, 
disabilities, and causes. Brain damage occurs as a consequence of an external force in the form 




of a direct impact or by acceleration or deceleration alone. The nature of the forces which cause 
trauma to the brain determine both the pattern and extent of damage, for example blast waves 
from an explosion have been identified as a cause of TBIs with specific characteristics (Maas, 
Stocchetti, Bullock 2008)(Maas, Stocchetti, Bullock 2008)(Maas, Stocchetti, Bullock 
2008)(Maas, Stocchetti, Bullock 2008)(Maas, Stocchetti and Bullock 728-741)(Maas, Stocchetti, 
and Bullock 2008, 728-741)(Maas, Stocchetti, and Bullock 2008, 728-741). In addition to the 
damage caused at the time of injury, brain trauma causes secondary injury, a variety of events 
that take place in the hours and days following the injury. These events include neurotransmitter 
release, free-radical generation, calcium mediated damage, gene activation, mitochondrial 
dysfunction, and inflammatory responses (Maas, Stocchetti, Bullock 2008). This secondary 
damage creates opportunities for medical intervention and targeted therapies to improve the 
outcome for the patient.  Currently the common treatment of TBI revolves around standardized 
approaches that follow predetermined guidelines for all patients. Knowledge of biomarker 
signatures of TBI diagnosis and potential outcome predictors could steer interventions and 
targeted therapies in the right direction for TBI victims.  
Biomarkers of physical brain injury can classify injury severity level as well as provide a 
prediction of the secondary damage which may occur in a specific patient. A number of studies 
have shown that the levels of a multitude of brain-specific proteins are altered both in 
cerebrospinal fluid (Buttram et al. 2007) and in blood (Berger et al. 2007)(Hergenroeder et al. 
2008)(Honda et al. 2010)(Rhind et al. 2010) are altered following a TBI. Using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), 31 proteins whose serum levels were 
altered were identified in TBI patients (Hergenroeder et al. 2008). In the three days following a 
TBI, serum levels of glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE) and S-




100B proteins are increased in patients who had suffered a TBI when compared to the control 
group (Honda et al. 2010). Mean serum concentrations of Hsp70 were significantly higher in TBI 
patients than in the control group (da Rocha et al. 2005). Many inflammatory and coagulation 
proteins may serve as candidate biomarkers of different characteristics of a TBI soon after the 
injury takes place. 
In the period following the initial injury, biomarker levels may serve as indicators of 
injury severity and prospective outcome. At all post-injury time points, higher serum levels of 
NSE, S100B, and myelin basic protein (MBP) were associated with worse outcome for children 
who had suffered from a TBI (Berger et al. 2007). In addition, serum tau protein levels in TBI 
patients at the time of hospital admission correlated with poor outcome (Liliang et al. 2010). 
Serum retinol binding protein 4 (RBP4) levels may serve as a predictor of a subsequent increase 
in intracranial pressure (Hergenroeder et al. 2008). Increased levels of Hsp70 are also seen in 
TBI victims with an increased possibility of death indicating a direct correlation between this 
biomarker and severity of the TBI (da Rocha et al. 2005).  
TBI provokes marked differences in an abundance of serum protein levels. In many 
studies, three biomarkers were individually measured using enzyme-linked immunosorbent 
assays. Using sensor-chip technology, multiple biomarkers associated with various time points of 
TBI, severity, and likely outcome could be simultaneously assessed. Classification of serum 
biomarkers in TBI patients may be useful in the prediction of secondary pathologies as well as in 
estimating the effectiveness of various therapeutic agents. Further research on the biosignatures 
of traumatic brain injuries of all severity levels could lead to better injury classification and 
therefore patient-specific therapies to improve the outcome of TBI patients.  
 




Biomarker Signatures of Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a condition characterized by persistent synovitis, systemic 
inflammation, and the presence of specific autoantibodies (particularly to rheumatoid factor (RF) 
and citrullinated peptide(CCP)) which affect many tissues and organs, but mainly attack synovial 
joints. Uncontrolled active rheumatoid arthritis causes joint damage, disability, decreased quality 
of life.  
Characterizing the biomarkers associated with RA onset can be useful in predicting the 
disease before symptoms become apparent and selecting the most advantageous treatment. 
Studies using enzyme-linked immunosorbent assays have shown that anti-citrullinated peptide 
(ACPA), anti- mutated citrullinated vimentin  (MCV) and IgM RF can be detected up to 10 years 
before RA diagnosis (Turesson et al. 2010).Additional prognostic markers studied include C-
reactive protein (CRP) or erythrocyte sedimentation rate (ESR),  ACPA , and rheumatoid factor 
(RF), or matrix metalloproteinase-3 (a proteolytic enzyme which is thought to play a pivotal role 
in joint destruction in RA) (Klareskog et al. 2008)(Mamehara et al. 2010). Biomarkers have also 
been used to predict the effectiveness of specific treatments on patients with RA. Results suggest 
T-lymphocyte expression of CD91 is a biomarker that signifies unresponsiveness to anti-TNF 
therapy, a biological disease modifying anti-rheumatic drugs (DMARDs) used to slow down the 
progression of joint destruction. Therefore CD91 expression may be used to identify potential 
responders and non-responders (Eriksson, Rantapaa-Dahlqvist, Sundqvist 2010). Developing a 
method to identify biomarker signatures associated with RA can be useful in preventing the 
appearance of disease symptoms and providing effective treatment. 
 
 




Biomarker Signatures Associated with Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia. The disease is 
incurable, degenerative, and terminal. Studies have been done using cerebrospinal fluid to 
identify biomarker signatures of the disease. Establishing a profile for the biomarkers of this 
disease might serve as signatures for the presence of Alzheimer’s pathology, and aid in the 
identification of patients suffering from Alzheimer’s among elderly individuals with late-life 
cognitive impairment. 
Using the Luminex assay, it was found that the CSF biomarker signature of AD are 
defined by Aβ1-42 and t-tau.  This signature appears to predict conversion from mild cognitive 
impairment to Alzheimer’s (Shaw et al. 2009). Increased levels of tau  in CSF are thought to 
occur after its release from damaged and dying neurons and tangles, large-scale accumulation of 
this least soluble of Aβ peptides into insoluble plaques in the AD brain, lead to decreased CSF 
levels of Aβ1-42. The combination of increased CSF concentrations of tau proteins, t-tau and 
phosphotau (p-tau), and the decreased concentrations of Aβ1-42 in a patients CSF are considered 
to be a pathological biomarker signature that can be used as a diagnostic tool for Alzheimer’s 
(Frank et al. 2003). 
Among the CSF biomarkers studied, CSF Aβ1-42 concentration appears to be the most 
sensitive analyte for the detection of AD, thereby indicating that CSF Aβ1-42 is the most 
informative single biomarker (Shaw et al. 2009). The use of the single biomarker Aβ1-42is 
inadequate as there is a portion of the healthy population who has higher levels of this indicator. 
A panel of biomarkers would be more useful means of diagnosing Alzheimer’s, predicting which 
individuals will progress to AD, as well as for monitoring the response of patients to various 
therapies in the hopes of developing improved treatment methods.  




Additional Uses of Biomarker Signatures 
In addition to the previously mentioned conditions, biomarker signatures are being 
characterized for multiple other uses. Biomarker signatures are being studied as a potential 
method to predict allograft tolerance for the identification of patients who can lower their 
amounts of immunosuppressive therapy, and as predictors of allograft rejection, so that damage 
can be prevented (Hernandez-Fuentes and Lechler 2010). Also, microarray analysis showed over 
1,500 genes exhibited significantly different expression level in saliva between oral cancer 
patients and controls. Seven of these cancer-related mRNA biomarkers exhibited at least a 3.5-
fold increase in the saliva of oral squamous cell carcinoma (OSCC) patients. Combinations of 
salivary RNA biomarkers allowed for distinguishing patients suffering from OSCC from the 
control group (Li et al. 2004).  
 
EXPERIMENT BACKGROUND 
Post Traumatic Stress Disorder 
Biomarker signatures will be sought in human saliva samples taken from patients who 
have experienced traumatic situations.  This model will allow us to determine unique and 
distinctive changes to the biomarker signature in exposed individuals before the onset of post 
traumatic stress disorder (PTSD). PTSD is a severe anxiety disorder that can develop after 
exposure to any event (physical or psychological) that result in psychological trauma. The 
Posttraumatic Stress Diagnostic Scale (PDS) is a questionnaire used to aid in the detection and 
diagnosis of PTSD. The PDS yields a total severity score (ranging from 0 to 51) that largely 
reflects the incidence of the symptoms of PTSD. Symptoms of PTSD include experiencing 
recurrent and intrusive recollections of the stressful event and persistent avoidance of things that 




remind them of the traumatic event. A PDS score provides diagnostic status, a count of the 
number of symptoms experienced, a rating of symptom severity, and a rating of the level of 
impairment of functioning. A drawback to the PDS is that administration of the questionnaire 
takes one to two hours. Symptoms of PTSD can last a long time and can be significant enough to 
cause impairment in social, occupational, or other areas of functioning. 
Efforts to prevent PTSD have been classified as either primary (intervention prior to the 
traumatic event) or secondary (intervention after the trauma) (Fletcher, Creamer, Forbes 2010). 
Due to the effect PTSD has on the lives of people who suffer from it as well as the effects PTSD 
has on the family of sufferers and on society, prevention and early treatment would be of 
extremely advantageous. In addition, the frequency of treatments which are ineffective is far too 
great, therefore having an early indicator of PTSD would be of great benefit to individuals 
(Fletcher, Creamer, Forbes 2010). PTSD creates an increased risk for illness in an individual as 
patients with a history of PTSD have long-lasting immune dysfunction. It has been shown that 
the number of lymphocytes, NK cell activity, and total amounts of certain immune related 
chemokines were significantly lower in patients with a past history of PTSD (Kawamura 
2001).Characterizing biomarker signatures associate with the development of PTSD following a 
traumatic event would be greatly useful in determining when treatment would be helpful and in 
improving the quality of life for the PTSD patient. 
 
Saliva as a Diagnostic Tool 
Saliva samples are easily accessible and have been shown to serve as a useful analyte for 
protein markers because saliva composition is influenced by many factors (Esser et al. 2008). 
The use of saliva as a medium for biomarker signatures has not been popular in the past due to 




the low concentration of these markers in saliva when compared to serum.  This has changed due 
to the development of highly sensitive and high-throughput assays such as microarray, mass 
spectrometry, reverse transcriptase polymerase chain reaction (RT-PCR), and other technologies 
which can be used to measure proteins even at concentrations found in saliva.  Many biomarkers 
are measurable in saliva, including heavy metals, hormones (e.g. cortisol and 
dehydroxyepiandrosterone (DHEA)), toxins and their metabolites, enzymes, immunoglobulins, 
other proteins and DNA (Soo-Quee Koh and Choon-Huat Koh 2007). 
About 18% of the saliva protein composition is involved in the immune response (Esser 
et al. 2008). It has also been found that there is an increase in the secretion of salivary stress 
biomarkers (salivary alpha amylase and salivary cortisol) under different stressful conditions 
(Wagner et al. 2009).  Chronic stress is associated with an increase in salivary cortisol, as well as 
with the depression of immune function seen by a decrease in by salivary IgA and lysozyme 
levels. Acute stress is associated with activation of the sympatho–adreno–medullary system, 
measured by salivary a-amylase and chromogranin A (Soo-Quee Koh and Choon-Huat Koh 
2007). These features of human saliva make it a simple an euseful analyte for diagnostic 
purposes. Possible limitations to using saliva as a diagnostic biofluids are normal variations 
among the population and difficulty storing the sample. 
 
TECHNOLOGIES FOR BIOSIGNATURE ANALYSIS 
Surface Plasmon Resonance (SPR) assays represent a novel approach to signature 
measurements. A surface plasmon is a traveling, temporary electromagnetic wave caused by 
charge-density oscillation at a metal-dielectric interface. Surface plasmon resonance can be 
employed to make sensitive measurements of molecular binding interactions.  One way in which 




SPR technology is utilized is by protein detecting microarrays. These assays utilize a wide 
variety of capture agents (antibodies, fusion proteins, DNA⁄RNA aptamers, synthetic peptides, 
carbohydrates, and small molecules) immobilized on a solid surface. (Tomizaki, Usui, Mihara 
2010). Each capture agent binds selectively to its target protein in a complex mixture, such as 
serum or saliva samples. Captured proteins are subsequently detected and quantified in a high-
throughput fashion, with minimal sample consumption. 
 SPR technology is used in high content assays with improved sensitivity compared to 
standard fluorescent microarrays (Unfricht et al. 2005).  This high sensitivity assay allows the 
measurement of immune system biomarkers that are normally found in very low concentrations 
in body-fluid samples that are easily obtained, such as saliva. By measuring 102 – 103 biomarkers 
simultaneously, it is possible to reveal patterns of biomarker expression that are indicative of 
stressed or diseased states.   
 
Grating-Coupled Surface Plasmon Enhanced Fluorescence (GCSPEF)  
The optical phenomenon of surface plasmon resonance can be employed to make 
sensitive measurements of molecular binding interactions.  For detection of small molecular 
weight or low concentration biomarkers, the generated surface plasmon can be used to enhance 
fluorophore excitation (Surface plasmon enhanced fluorescence; SPEF) and improve optical 
collection efficiency from fluorescently labeled secondary antibodies or biomarkers directly 
labeled in a sample.  GCSPEF introduces the use of fluorescent tags attached to a captured 
analyte (Figure 1). This technology was developed by the Lynes laboratory in collaboration with 
the biotechnology company Ciencia Inc. GCSPEF can be used for cell-based assays, protein 
assays, and many other functional purposes i.e. to obtain a measurement of cell function by 




means of measuring the soluble proteins secreted from stimulated cells (Jin et al. 2006). 
Advantages of GCSPEF over more widely used techniques include its need for small sample size 
(1 ml), microvolumes of detection reagents, and for its ability to measure hundreds of 
simultaneous real-time measurements of different analytes. 
 In GCSPEF the analyte is flowed over a sensor chip which has been prepared with 
specific immobilized receptors (which can be antibodies or other proteins). The sensor chips are 
covered with a gold surface. During an experiment, the captured analystes are illuminated with 
light that couples with the electrons on the grated surface of the gold plated GCSPEF chip to 
form a surface Plasmon (Jin et al. 2006). Because plasmons do not propagate far into gold, 
hundreds to thousands of interactions can be analyzed on one chip. Sensor chips will be 
configured with capture reagents that measure proteins of interest (e.g. cytokines, stress 
hormones, antibodies, and other soluble factors). Antibodies or capture ligands are covalently 
attached to the gold surface of sensor chips on spots, called Regions of Interest (ROIs) which 
allows for specific binding of analytes or cells to occur which changes the refractive index at the 
interface.  
GCSPEF is able to detect and measure the presence of hundreds of different analytes 
simultaneously from a small sample volume.  ROIs are spatially organized on a gold-plated 
sensor chip so that the specific binding of different analytes in a mixed sample can be measured 
simultaneously by passing the sample over the sensor chip and recording changes in the SPR 
angle at different ROIs. As an analyte is captured on a ROI, the SPR angle (the angle of minimal 
reflection due to maximum coupling) increases. The camera within the GCSRPI machine scans 
through a variety of angles to find the SPR angle, which is dependent upon the index of 
refraction at the metal interface. The SPR angle can be increased due to interactions between 




analytes and immobilized capture molecules on the chip which that cause an increase in the 
index of refraction. The SPR angle can be correlated to the amount of analyte that has bound. 
GCSPEF will be specifically useful in my project since hundreds of different regions of the chip 
can be independently analyzed simultaneously using sub-milliliter sample volumes (Unfricht et 
al. 2005).  
 
Surface Plasmon Enhanced Fluorescence (SPEF) 
The Surface Plasmon Enhanced Fluorescence, SPEF, assay allows for increased 
sensitivity for detection and quantification of analytes that are too small or too dilute to be 
detected by traditional GCSPEF. For detection of small molecular weight or low concentration 
biomarkers, the generated surface plasmon can be used to enhance fluorophore excitation to 
improve the optical collection efficiency from fluorescently labeled secondary antibodies (Figure 
3).  Due to the sensitivity of the SPEF assay, it is ideal for highly sensitive fluorescent protein 
microarrays. Gold plated chips are used in the SPEF assay because a metal dielectric interface is 
needed for SPR. The two platforms (GCSPEF and SPEF) utilize the same chip and the same 
machine; therefore independent measurements can be made using both methods from the same 
ROIs in sequence during a single experiment.  
The SPEF assay can utilize a traditional sandwich immunoassay format (Figure 2) which 
enables the large-scale analyses of protein interactions across the entire proteome in a high-
throughput fashion with less consumption of the sample. Capture agents are immobilized on a 
gold surface and target proteins in the sample are captured. Fluorescently conjugated detection 
antibodies are then flowed over the chip which allows for the measurement of captured proteins 
in specified ROIs.  The SPEF assay is a high content technology, many measurements from the 




same sample can be done simultaneously. The technology is versatile in that many different 
types of biomarkers can be measured in conjunction with one another. The high sensitivity of the 
system allows for the use of  small sample volume, a very useful feature of the technology in 
diagnostic sciences since sample sizes are often extremely limited.  
In the future, new instruments can be used in order to reduce both cost and size of 
instruments so that these technologies can move from the laboratory to the field to be used in 
clinical diagnostics. There are also opportunities to improve the sensitivity of the system by 
increasing the amounts of immobilized capture molecules, properly orienting the capture 
molecule for maximum accessibility of analyte to binding sites, and minimizing non-specific 
binding which affects the net sensitivity of the assay. One current approach is the coating of 
chips with various surface chemistries that allow for more predictable orientation of binding of 
the capture molecule (Jin et al. 2006).  
 
Salivary Biomarkers of Stress Project 
Saliva samples were collected from trauma patients at two different time points following 
the initial injury. In order to quantify the differential expression profiles of interleukins, 
chemokines, TNF and interferon families, and other related stress proteins (e.g. heat shock 
proteins, melatonin, and procalcitonin) traditional enzyme-linked immunosorbent assay (ELISA) 
as well as surface Plasmon enhanced fluorescence (SPEF) techniques were utilized.  
 
MATERIALS AND METHODS 
Saliva samples were collected by our collaborators at UCLA from patients who had been 
assaulted (either shot or stabbed. Saliva samples were collected using a “lollipop” style device 




that patients suck on. The device has a filter and the salivary fluid is absorbed through it and 
collected. Roche complete protease inhibitor cocktail tablets were used for stable storage of the 
samples. Saliva samples were frozen in microcentrifuge tubes. The saliva samples were shipped 
frozen to the University of Connecticut. Samples were stored in the -80oC ultrafreeze until ten to 
fifteen minutes before they were analyzed.. Samples were allowed to thaw by remaining at room 
temperature for around ten minutes.  
The enzyme-linked immunosorbent assay (ELISA) can also be used to detect the 
presence and concentrations of an antibody or antigen analyte in a sample. An unknown amount 
of the analyte is captured by specific antibodies which have been fixed to a well surface. 
Secondary antibody linked to an enzyme is then washed over the surface so that it may bind to 
antigen captured previously. A substrate is then added which the enzyme can convert to a 
detectable, colored signal whose absorbance can be measured by spectrophotometer.  
 
ELISA Protocol for Salivary Biomarkers-Alpha Amylase and Salivary Cortisol 
To determine the saliva sample dilution with PBS-T (dissolve 8g of NaCl, 0.2g of KCl, 
1.44g of Na2HPO4, 0.24g of KH2PO4, and 2ml of tween-20 in 800 ml of distilled H2O, adjust pH 
to 7.2 and adjust volume to 1L with additional distilled H2O)  that should be used for SPEF 
analysis, enzyme-linked immunosorbent assays were done on various analytes including salivary 
alpha-amylase and cortizol.  96-well Immulon 2 HB plates (Dynatech Laboratories, Inc.) were 
coated in triplicate with capture antibody (mouse anti amylase at 1 µg/mL from Santa Cruz or 
mouse anti cortisol from ABD serotech) with 100ul per well. Plates were incubated overnight at 
4oC. Plates were then washed with PBS-T (PBS with 0.2% NaN3 and 0.005% Tween 20, pH 7.2) 
using the ELx405 autoplate washer. The wells were then blocked with 2%BSA in PBS-T using 




200µl per well and incubated for 1 hour at 37o C. Plates were washed again before adding 
standard human salivary amylase or human salivary cortisol dilutions starting with 1 mg/ml in 
PBS-and continuing with an 11-step doubling dilution series (100ul/well). Plates were incubated 
for 2 hours at 25oC and then washed again as done previously.  The detection antibody cocktail, 
(detection anti-amylase, goat polyclonal IgG from Santa Cruz or polyclonal rabbit anti-cortisol 
from ABD Serotech) 1 ug/mL in PBS-T, was added (100µL/well) and incubated for 2 hours at 
25oC.  100 µL of detection anti-goat IgG-biotin antibody (Rabbit Anti-Goat IgG-Biotin from 
Southern Biotech at 0.5 mg/mL) at 1/5000 in PBS-T was added to each well and incubated for 1 
hour at 37oC. Plates were washed then Streptavitin-conjugated alkalike phosphate at a dilution of 
1/500 (100µL/well) was then added to each well and plates were incubated for 20 minutes at 
37OC before a final wash.  Wells were then coated with 100 µL substrate buffer (9.7 mL 
diethylamine, 0.01 g of MgCl2·6 H20, 0.02 g NaN3 and 90 mL H20, pH 9.8) containing one mg 
para-nitrophenylphosphate (PNPP) per mL. A kinetic plate read at 405nm was performed for ten 
minutes using a SpectraMax M2 plate reader (Molecular Devices). Nonlinear regression software 
(SOFTmax PRO from Molecular Devices) was used to generate a best-fit curve and its equation. 
 
ELISA Protocol for IL-1beta 
 To determine the saliva sample dilution (with PBS-t) that should be used for SPEF 
analysis, enzyme-linked immunosorbent assays was also done on IL-1 beta.  96-well Immulon 2 
HB plates (Dynatech Laboratories, Inc.) were coated in triplicate with capture antibody (Mouse 
anti-human IL-1β with 2 ug/mL PBS-t from R&D Systems with 100ul per well. Plates were 
incubated overnight at 4oC. Plates were then washed with PBS-T (PBS with 0.2% NaN3 and 
0.005% Tween 20, pH 7.2) using the ELx405 autoplate washer. The wells were then blocked 




with 2%BSA in PBS-T using 200ul per well and incubated for 1 hour at 37o C. Plates were 
washed again before adding standard human salivary IL-1 beta dilutions from 2,000 pg/ml in 
PBS-t and unknown dilutions in halves from 1:5 for an 11 step dilution series (100ul/well). 
Plates were incubated for 2 hours at 25oC and then washed again as done previously.  The 
detection antibody cocktail, biotinylated goat anti-human IL-1β-biotin at 400 ng/mL with PBS-T 
1 ug/mL was added (100µL/well) and incubated for 2 hours at 25oC.  Plates were washed then 
Streptavitin-conjugated alkaline phosphate at a dilution of 1/500 (100µL/well) was then added to 
each well and plates were incubated for 20 minutes at 37OC before a final wash.  Wells were then 
coated with 100 µL substrate buffer (9.7 mL diethylamine, 0.01 g of MgCl2·6 H20, 0.02 g NaN3 
and 90 mL H20, pH 9.8) containing one mg mg para-nitrophenylphosphate (PNPP) per mL. A 
kinetic plate read at 405nm was performed for ten minutes using a SpectraMax M2 plate reader 
(Molecular Devices). Nonlinear regression software (SOFTmax PRO from Molecular Devices) 
was used to generate a best-fit curve and its equation. 
 
SPR Chip Preparation 
SPR sensor chips were washed with 95% ethanol (EtOH) exhaustively for 30 sec. The 
chips were then washed exhaustively with ddH2O for 60 sec. Chips were dried under filtered 
pressurized air and placed into a plastic chip holder to keep clean until printing. In order to print 
capture antibodies onto the gold surface of the chips, a 384 well plate was used, v-bottomed 
wells (Table 1) were filled with their respective antibody solutions to spot capture antibody 
microarray on the cleaned gold chip. The printing program used for biomarker signature analysis 
in all human saliva samples was written using the Spotblot II software. Chips were printed under 




high humidity using a robotic spotter by Arrayit Microarray Technology. Chips were kept in the 
humidity chamber of the robotic spotter for 60 minutes before use. 
 To analyze sample set two saliva samples, the chemical cross-linker 
dithiobis(succinimidyl propionate), DSP, was coated on the gold surface of the chips in order to 
improve the method for immobilizing proteins on the chip surface. 4 mg of DSP, dithiobis 
(siccinimidyl propionate) from Thermoscientific were dissolved in 1 mL of dimethylsulfoxide 
(DMSO) from Fisher Scientific. 300 µL of the solution was spread over the gold surface and 
allowed to sit for 30 minutes. The chips were then washed by rinsing them with DMSO followed 
by a rinse with ddH2O. Spotting proteins to the activated gold surface was done immediately 
following the DSP coating.  
SPEF sensor chips with was washed with 95% EtOH exhaustively for 30 seconds then 
washed exhaustively with ddH2O for 60 sec. Chips were dried under filtered pressurized air and 
placed into a plastic chip holder to keep clean until printing. In order to print capture antibodies 
onto the gold surface of the chips, a 384 well plate was used, v-bottom wells were filled with 
their respective antibody solutions (Table 1) to spot capture antibody microarray on the cleaned 
gold chip. The printing program was made using the Spotblot II software for this experiment to 
be used for biomarker signature analysis in all human saliva samples. Chips were printed under 
high humidity using a robotic spotter from Arrayit Microarray Technology. Chips were allowed 
to stand for 60 min in the humidity chamber of the robotic spotter before proceeding. 
 
Sample Analysis Protocol 
Bench top chip fluidic device was washed by circulating PBS-T through the fluidics at 
high speed for 5 min. Fluidics were then primed with 2% BSA in PBS. Dry, printed chips were 




inserted into the chip-holding chamber and were blocked using 2% BSA in PBS at 0.5 ml/min 
for 30 min. The chips were then washed by running PBS-T at 0.5 ml/min for 5 min. Saliva 
samples were thawed immediately before use. Human saliva sample (0.25 ml) was diluted with 
PBS-T up to a total volume of 1.5 ml (1:5 dilutions). One ml of sample was drawn into the 
fluidics before shunting the end of the waste tube back into the sample holder. The sample was 
recirculated at 0.5 ml/min for 60 minutes. The chip was then washed by running PBS-T at 0.5 
ml/min for 5 min. 1.5 ml of detection antibody cocktail in PBS-T was recirculated at 0.5 ml/min 
for 60 minutes (use Table 2 for antibody information and dilution factors). The chips were then 
washed by running PBS-T at 0.5 ml/min for 5 min. Streptavidin-alexa647 cocktail was 
recirculated at 0.5 ml/min for 30 min. Chip was washed by running PBS-T at 0.5 ml/min for 10 
min. To obtain fluorescent data from the cortisol and amylase secondary detection antibodies, 1.5 
ml of anti-goat IgG-alexa647 and anti-rabbit IgG alexa-647 cocktail in PBS-T was recirculated at 
0.5 ml / min for 30 min (See Table 3 for reagent dilution factors). Chips were washed by running 
PBS-T at 0.5 ml/min for 10 min.  
To analyze saliva sample set two, an eight chamber bench top chip fluidic device (a 
device with eight separate inflow tubes, chip chambers, and outflow tubes with uniform fluid 
movement controlled by a central pump) from Masterplex was primed with 2% BSA in PBS. 
Dry, printed chips were inserted into the chip-holding chambers and were blocked using 2% 
BSA in PBS at 0.5 ml/min for 30 min. The chips were then washed by running PBS-T at 0.5 
ml/min for 5 min across the sensor chip surface. Saliva sample were thawed immediately before 
use. 0.25 ml of human saliva sample was diluted with PBS-T  to 1.5 ml (1:5 dilution). 1 ml of 
diluted sample was drawn into the fluidics before moving the end outflow tube back into the 
sample chamber enabling recirculation with the 0.5 ml reserve in the sample tube. The sample 




was recirculated at 0.5 ml/min for 60 minutes. The chip was then washed with PBS-T at 0.5 
ml/min for 5 min. 1.5 ml of detection antibody cocktail (Table 2)  in PBS-T was recirculated at 
0.5 ml/min for 60 minutes (use Table 2 for antibody dilution factors). Chip was washed by 
running PBS-T at 0.5 ml/min for 5 min. Streptavidin#alexa647 (from, anti-goat IgG#alexa647 
and anti-rabbit IgG alexa#647 (from Invitrogen Molecular Probes) cocktail in PBS-T was 
recirculated at 0.5 ml / min for 30 min (Table 3). Chips were washed by running PBS-T at 0.5 




Saliva samples were divided into low stress or high stress groups by our collaborators at 
UCLA according to their post traumatic stress diagnostic scale (PDS) score (Figure 4).  Samples 
were collected 2-3 weeks apart and called “visit 1” and “visit 2”. All samples were measured for 
the presence of immune/stress associated biomarkers using SPEF microarray. Using both 
parametric and non-parametric T-tests, groups were analyzed for differenced between single 
biomarkers or for changes in levels of a single biomarker. Parametric tests were useful in 
examining the levels of individual biomarkers among groups, while non-parametric tests were 
used to compare differences in biomarker levels between groups. Differences in biomarker levels 
between groups, and the change in biomarker levels between visits were analyzed for statistically 









ELISA Validation of Reagents 
Enzyme-linked Immunosorbent Assays (ELISAs) were conducted in order to determine 
the saliva sample dilution that should be used for GCSPEF and SPEF assays.  A saliva sample 
was analyzed in comparison to a standard 11-step dilution series of each biomarker. Alpha-
amylase was diluted in halves from 1 mg/mL, IL-1 beta from 2000 pg/mL, and salivary cortisol 
from 100ng/mL. Control saliva samples and PTSD saliva samples were diluted from a 1:1 
dilution to a 1:5 dilution in each experiment. Based on the ELISA results, it was determined that 
physiologically relevant measurements of these biomarkers could be made with a saliva sample 
dilution of 1:5 in PBS-T.  
 
 PTSD Saliva Samples: Sample Set 1 
Surface Plasmon enhanced fluorescence (SPEF) was utilized in order to quantify the 
differential expression profiles of interleukins, chemokines, TNF and interferon families, and 
other related stress proteins (e.g. heat shock proteins, melatonin, and procalcitonin) in saliva 
samples obtained from PTSD patients at two different time points. The samples were divided 
into four categories, high stress visit 1, high stress visit 2, low stress visit 1, and low stress visit 
2. Several patterns are apparent among the biomarkers examined. A complete heat map of all of 
sample set 1 can be seen in Figure 6.  
Analysis of 39 stress exposed individuals for the presence of 26 immune and/or stress 
associated biomarkers revealed one biomarker, MMP-9, that was significantly different between 
high and low stress groups (Figure 6). Dividing stress groups samples into 2 visits indicated that 
IL-2 levels are significantly higher in the high stress visit 1 group (Figure 7).  




Sample set 1 revealed no significant intergroup variations in the additional biomarkers 
examines (as listed in Table 1).  Because direct analysis of biomarker levels revealed few 
differences between groups, we looked at the changes in the levels of biomarkers that occurred 
between visit 1 and visit 2 in each patient. This integrative analysis revealed that levels of C-
reactive protein (Figure 9) declined more in the low stress group and that levels of cortisol 
increased more in the low stress group (Figure 8). Ultimately, our analysis is limited by sample 
size and the ability of the PDS to accurately group individuals into high and low stress groups. 
However, the observed differences indicate molecular patterns of stress exposure may exist.  
 
PTSD Saliva Samples: Sample Set2 
 36 saliva samples were analyzed in sample set 2 with the use of DSP surface chemistry 
(Figure 10). Dividing stress groups samples into two time points, visits 1 and 2, indicated 
significant differences in levels IL-18 binding protein (IL-18 Bpa) among the groups in sample 
set 2 (Figure 11). Additionally, we found that levels of IL-8 (Figure 12) and alpha-amylase 
(Figure 13) decreased more in the low stress group. Again, our analysis is limited by sample size, 
inter-assay variability and the ability of the PDS to accurately group individuals into high and 
low stress groups. However, these variations in biomarker level, or changes in biomarker level, 
indicate that biomarker signatures of psychological stress exposure may be present.  
 
DISCUSSION 
MMPs are a family of enzymes which have the ability to degrade components of the 
extracellular matrix. These degrading enzymes are upregulated in inflammatory processes. Our 
sample set 1 data revealed levels of salivary MMP-9 that were significantly higher in the low 




stress group when compared to the high stress group . This observation implies that there is an 
association between MMP-9 and psychological factors. It was found that there are significant 
positive associations between MMP-9 and depression, hostile affect, cynicism, and significant 
negative association with a sense of coherence (Garvin et al. 2009). Cancer patients with 
elevated symptoms of depression, chronic stress, and low social support also express elevated 
MMP-9 levels in tumor associated macrophages as well as in CD68+ cells (Lutgendorf et al. 
2008). An explanation for the connection between elevated MMP-9 levels and stress is through 
the effects of stress hormones, such as norepinephrine and cortisol. Isolated human macrophages 
stimulated with these stress hormones in vitro increased MMP-9 production (Lutgendorf et al. 
2008).  
Our sample set 1 data also showed higher CRP levels in the high stress when compared to 
the low stress group. C-reactive protein (CRP) is a protein found in blood, levels of which rise in 
response to inflammation. It has been shown that there is a greater CRP concentration in lower 
socioeconomic status (SES) groups defined by occupational status implying an increase in CRP 
levels associated with a more stressful lifestyle (Owen et al. 2003). Low SES is associated with 
increased risk of coronary heart disease and immune-related disorders which could in part be 
reflected by the greater CRP concentration (Owen et al. 2003).   
Our sample set 1 data suggests that levels of cortisol increased more in the low stress 
group from visit 1 to visit two when compared to the high stress group. Previous research 
suggests that a stronger cortisol response at the time of exposure to a traumatic event has a 
protective effect against posttraumatic stress disorder symptoms. It was shown that a lower rise 
in salivary cortisol levels was associated with an increase in risk of PTSD at both one month and 
6 months (Yehuda 2002). However, conflicting data has been found in a separate study. In that 




work, patients who were PTSD positive at 1 month were found to have lower salivary cortisol 
levels on the day 2 assessment when compared to those who did not have PTSD (McFarlane et 
al. 2010).  
In sample set 2, IL-18 binding protein (IL-18 Bpa) was found in increased levels in the 
low stress, visit when group when compared to the other three groups. IL-18 binding protein 
binds to IL-18 and blocks its biological activity. Therefore, IL-18 is an inhibitor of the Th1 
cytotoxic T cell response of the immune system (Novick et al. 1999). Interleukin-18 (IL-18) is a 
pro-inflammatory cytokine which plays a role in a variety of conditions and diseases including 
infections, autoimmunity, and cancer. IL-18 levels are elevated by activation of the 
hypothalamic–pituitary–adrenal (HPA) axis and may be down-regulated by the activation of the 
para-sympathetic nervous system (Sugama and Conti 2008). Data obtained in humans or in 
animal models demonstrated an association between IL-18 levels and psychiatric disorders 
(Sugama and Conti 2008). It has been shown in humans that serum levels of IL-18 were elevated 
in depression, panic disorders and other stressful conditions (Kokai et al. 2002). Our data shows 
increased levels of an IL-18 inhibitor in the low stress group. Further data analysis and a final 
PTSD diagnosis in the patients will be needed to evaluate the linkage between IL-18 binding 
proteins and PTSD. 
Sample set 2 results indicated that levels of IL-8 and alpha-amylase decreased more in 
the low stress group (between visits 1 and 2) when compared to the high stress group. IL-8 is a 
chemokine produced by macrophages and other cell types. IL-8 functions as a chemoattractant, 
and is also a potent angiogenic factor. It has been shown that serum IL-8 concentration in women 
with psychological symptoms was significantly higher than that in women without psychological 
symptom indicating a link between IL-8 and psychological stress (Yasui et al. 2007). 




Amylase is a calcium-containing metalloenzyme that hydrolyzes starch in the oral cavity 
and is also considered to play an important role in binding to oral bacteria (Nater et al. 2005). 
Salivary alpha-amylase levels were found to respond to both physical and psychological stress. 
While alpha-amylase levels seem to rise following physical stress, the response to a 
psychological stress appears inconsistent (Nater et al. 2005). This inconsistency might be due to 
the psychological nature of the stressors employed or due to experimental details, such as 
measuring alpha-amylase levels at inappropriate time points. However, other studies have shown 
marked increases in salivary alpha-amylase following psychosocial stress, indicating a stress-
dependent activation of salivary alpha-amylase (Nater et al. 2006). 
Our sample set 2 results indicate an increase in salivary alpha amylase 2-3 weeks 
following the traumatic event in the high stress group when compared to the low stress group. 
The increase in alpha-amylase between visit 1 and visit 2 in the high stress group may be 
associated with the greater psychological trauma experienced.  
 
Further Experiments 
Further analysis of the data already generated will include combining data from multiple 
biomarkers into potential biomarker signatures. Additionally, grouping suites of biomarkers will 
be done to assess the presence of immune response types (ex. TH1 vs. TH2 responses, pro-
inflammatory vs. anti-inflammatory responses, etc.). It is possible that an integrative analysis 
will reveal patterns or signatures that are characteristic of different types of psychological stress. 
Having a molecular mechanism of diagnosing PTSD, quicker diagnosis can be made without 
filling out a time-consuming questionnaire (the PDS). A molecular analysis of serum or saliva 




could be used in place of the more traditional psychological screening exams to improve 
diagnosis of PTSD and lead to better therapeutic outcomes. 
SPEF is a high content assay with improved sensitivity (with detection limits as low as 
500 fg/ml) compared to standard fluorescent microarrays. There are other protocol modifications 
that could still be examined as ways to further improve the speed and accuracy of the GCSPEF 
and SPEF technologies. These modifications include experimentation with different surface 
chemistries, different blocking reagents, and altering the antibody and sample concentrations. 
Variation between chips, reagents, and assays pose a potential difficulty among inter-assay 
comparisons of SPEF experimental results. 
Our current research focuses on the measuring salivary biomarkers associated with 
psychological stress and trauma. We have already observed significant observable differences 
between affected populations and controls for multiple immune biomarkers. By grouping these 
differences into patterns we hope it identify signatures of stress associated with disease, trauma, 
or toxicant exposure that could be used for clinical diagnosis. Additional statistical analysis 
needs to be done to further analyze our data obtained from psychologically stressed patients. 
SPEF could be used in the diagnostic world to speed up the diagnosis of many diseases by 
looking for many markers of the disease in real time without a requirement for extra labeling 
steps, such as fluorescence. SPEF technology may be useful in predicting the development of 
post traumatic stress disorder. Utilizing knowledge of biomarker signatures for PTSD, it may be 
possible to determine what initially triggered the psychological disorder, making it feasible to 
control PTSD before it progresses in severity.  
In addition to the previously mentioned purposes, the data collected through our 
experiments will provide research supporting the accuracy and wide range of uses for GCSPEF 




and SPEF technologies. Additionally, the saliva experiments further supposed the possibility of 
utilizing saliva as a safer, less invasive diagnostic biofluid. To further develop the use of saliva 
as a diagnostic biofluid, more research needs to be done to determine the differences in salivary 
content throughout the day and night as well as normal differences among the population. The 
stability and ideal storage methods of saliva also need to be further examined for ideal accuracy 
in the results of studies using saliva as a biofluid. 
  
Future Directions 
The use of biomarker signatures to diagnose psychological or chemical stress is a rapidly 
expanding field of research.  Ultimately, using biomarker signatures, effects of different stresses 
may be better predicted and controlled and insight can be provided as to some of the health 
consequences which may result. Our experimental protocols and technologies utilized can be 
expanded to include a wider variety of stress forms including traumatic brain injury, rheumatoid 
arthritis, toxicant exposure, cancer and many other forms of stress. In addition, other biofluids 
may be assayed for biomarker signatures (i.e. blood plasma from patients who have been 
exposed to various chemical agents). Another application of SPEF technology, in addition to 
protein interactions, is cell capture using antibodies to cell-surface protein which provides the 
possibility of cell surface biomarker signature studies.  
In summary, we have shown that variation in biomarker levels exist among different 
stress levels in patients diagnosed with post traumatic stress disorder. These differences in 
biomarker levels allow for further statistical analysis top develop patterns of biomarker 
signatures of post traumatic stress disorder diagnosis, onset, severity, and the most effective 
treatment options. The assays remain to be optimized, and any analysis of the data must take into 




account the differences between protocols utilized, individual experimental assay conditions, and 
differences among the samples used. These assays may be used in the future for the study of 
additional biological signatures of disease and could provide a novel method of diagnosis.  
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Figure 2: Traditional Sandwich Immunoassay Format 







Figure 3: SPEF Technology Design 
 
 
Figure 4: Biomarker signatures of PTSD Experimental Design 




















*Experiments completed from 06/08/10-09/10/10 



















Figure 6: Sample Set : 1MMP-9 Data









































































Figure 9: Sample Set 1: CRP  Data














*Experiments completed from 11/17/10-01/10/11 
 















Figure 11: Sample Set 2: IL-18 Binding Protein Data 








* Mann-Whitney U test used 
 
Figure 12: Sample Set 2: IL-8 Data 


























*Paired T-test and Mann-Whitney U tests used 
 
Figure 13: Sample Set 2: Alpha-amylase Data 








Type Rationale Detection Strategy Ab Vendor Plate 
position 
Dilution buffer Control    O1 
BSA control    O2 





Goat – poly α-IL-1β-biotin 




IL-1 ra Anti-inflammatory 
Response  
 
Goat – poly α-IL-1ra-biotin 




IL-2 Th1 Cytokine {Chiappelli, 2006 
#5} 
Goat – poly α-IL-2-biotin 




IL-4 Th2 Cytokine {Chiappelli, 2006 
#5} 
Goat – poly α-IL-4-biotin 




IL-5 Th2 Cytokine  Goat – poly α-IL-5-biotin 







Goat – poly α-IL-6-biotin 







Goat – poly α-IL-8-biotin 







Goat – poly α-IL-10-biotin 




IL-12 T cell stimulating 
factor 
 
Goat – poly α-IL-12-biotin 







Goat – poly α-IL-13-biotin 







Goat – poly α-IL-17-biotin 








Rat poly α-IL-18-biotin 
Str. – Alexa 647 
MBL O14 
IL-18Bpa IL-18 binding 
protein 
 
Goat – poly α-IL-18-biotin 




IL-33 Th2 stimulating 
cytokine 
 
Goat – poly α-IL-33-biotin 




Leptin Adiposity signal  Rat – poly α-Leptin-biotin 




Interferon-γ Th1 cytokine {Chiappelli, 2006 
#5} 
Goat – poly α-IFN-γ-biotin 








Goat – poly α-TNF-α-biotin 




MMP-9 gelatinase {Menon, 2006 
#11} 
Goat – poly α-MMP-9-
biotin 









Rat– poly α-CRP-biotin 











Rabbit – poly α-Cortisol 
 




α-amylase Salivary amylase {Wagner,  #8} 
increased with 
stress 








MCP-1 Monocyte, Tm 
chemokine 




Goat – poly α-MCP-1-
biotin 









IgA Secretory Ig {Takatsuji, 2008 
#10} 
M.mono. α-human kappa 
light chain- biotin 
M.mono α-human lambda 
light chain – biotin 




IgG Human Ig  M.mono. α-human kappa 
light chain- biotin 
M.mono α-human lambda 
light chain – biotin 
Str. – Alexa 647 
 P2 
IgM Human Ig  M.mono. α-human kappa 
light chain- biotin 
M.mono α-human lambda 
light chain – biotin 
Str. – Alexa 647 
 P3 
IgE Human Ig  M.mono. α-human kappa 
light chain- biotin 
M.mono α-human lambda 
light chain – biotin 
Str. – Alexa 647 
 P4 
MOPC Mouse IgG 
Negative control 




















control Str.-Alexa647  P8 
BSA Protein Block 
NSB control 
control   P9 
Dilution Buffer Negative Control control   P10 
 
 
TABLE 2 Detection Antibody Cocktail: Antibody Dilution Factors 
Analyte (human) FL 
Detection 
Strategy 









Volume of stock 
antibody in 1.5 
ml PBS-T 
Dilution buffer      
BSA      





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 





0.1- 0.4 µg /mL 0.25 µg / mL 7.5 µl 





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 





0.5- 2 µg/ mL 1.25 µg/ mL 7.5 µl 









0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 




3.6 µg /mL 
20 ng /mL 20 ng /mL 8.3 µl 





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 
IL-18 2O- biotin* / 
avidin-
alexa647 
MBL 1 mg/mL 1:1000 dillution 1:1000 
dillution 
1.5 µl 





200 ng/ml 200 ng/ml 8.3 µl 





0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 





0.5- 2 µg/ mL 1.25 µg/ mL 7.5 µl 




9µg / mL 
50 ng/ mL 50 ng / mL 8.3 µl 




50µg / mL 
0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 




50µg / mL 
0.1- 0.4 µg /mL 0.25 µg /mL 7.5 µl 
C-reactive 
protein 




22.5µg / mL 
125 ng / mL 125 ng / mL 8.3 µl 





5mg / mL 
? 1:1000 1.5 µl 






200 µg / mL 
1:30 – 1:3000 1:1000 1.5 µl 




50 µg/ mL 
2- 4µg / mL 0.3 µg / mL 9 µl 




IgA 2O α-κ + α-




1mg / mL 
1:2000 – 
1:4000 
1:2000 1 µl 
IgG 2O α-κ + α-




500 µg / ml 
1 µg / ml 0.5 µg / ml 1 µl 
IgM 2O α-κ + α-




500 µg / ml 
1 µg / ml 0.5 µg / ml 1 µl 
IgE 2O α-κ + α-




500 µg / ml 
1 µg / ml 0.5 µg / ml 1 µl 




goat Ig – 
Alexa647 
Invitrogen 
2mg / ml 




rabbit Ig – 
Alexa647 
Invitrogen 
2mg / ml 




2mg / ml 
? 400 ng / ml 2µl stock -> 1 ml 
PBS-T, mix, add 
150µl to final of 
1.5 ml 
BSA      
Dilution Buffer      
Antibodies from R&D Systems 
Table 3 Detection Antibody Cocktail: Reagent Dilution Factors 
 








Volume of stock det. 
reagent in 1.5 ml 
PBS-T 
Dilution buffer     
BSA     






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  










200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  




rabbit IgG (H+L) 
alexa647 2mg/ml 
5 ug / ml 3.7 µl 






5 ug / ml 3.7 µl 










200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  
Listeria 
monocytogenes 






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  
Metallothionein     






200 ng / ml 1 µl of stock in 1 ml 
of PBS, mix, add 
150 µl  
MOPC     
Goat anti-mouse 
IgM 
    
Rabbit anti-mouse 
CCR3 
    
Biotin-mIgG     
BSA     
Dilution Buffer     
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